Dr. Peter Marks emphasized the FDA's approval as a significant enhancement in vaccination accessibility, providing "a new option for receiving a safe and effective seasonal influenza vaccine potentially with greater convenience." He highlighted the importance of making vaccines more accessible, especially for busy families.
With the new approval of FluMist for home use, it allows individuals between 2 and 49 years to receive their flu vaccination with a prescription, and ensures safety and effectiveness in a more preferred, nasal method.
FluMist Home service, created by AstraZeneca, incorporates an online questionnaire that allows pharmacists to evaluate and prescribe the vaccine, thus streamlining the process and making it more user-friendly.
The CDC reported that flu affects about 8% of the U.S. population annually, and the nasal vaccine's convenience can significantly increase vaccination rates among those deterred by traditional methods.
Collection
[
|
...
]